Abeona Buys Phase 3 EoE Drug, Raises $30M at $3.75 a Share
ABEO is trading near its 52-week low of $2.3 (14% above the low) on elevated volume (5.2× avg).
Summary
Abeona is adding a second late-stage asset, acquiring APT-1011 (now ABO-801) from Ellodi Pharmaceuticals for $20 million in stock with no upfront cash, plus up to $30 million on regulatory approval, up to $30 million in sales milestones and tiered royalties. The once-daily oral tablet targets eosinophilic esophagitis, a condition affecting roughly 360,000 people in the U.S.; Abeona plans to start a Phase 3 trial in mid-2027 with topline data expected late 2028. To fund it, the company raised $30 million in a private placement at $3.75 a share — 6.4 million shares plus pre-funded warrants for about 1.6 million shares — with Nantahala, Marshall Wace and Perceptive participating. Q3 muddied the picture: revenue of $13.491 million missed the $16.484 million consensus even as the 8-cent loss beat the 15-cent estimate, and ZEVASKYN product revenue rose 18% sequentially to $13.5 million with 15 total patient treatments since launch. Cash stood at $134.9 million before the placement, and shares were down 11.51% at $3.69 premarket.
At the time of this announcement, ABEO was trading at $2.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $149.8M. The 52-week trading range was $2.30 to $7.65. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Benzinga.